Previous 10 | Next 10 |
Liquid biopsies provide hope for quicker and more accurate early-stage cancer detection across a wider range of cancer types with a simple blood test. Using current standard of care, only about 25% of cancers are detected via screening. The remaining 75% are detected when the patient ...
ARKK has continued its massive downward move despite its implosion in 2021. It has lost 56% YTD as its underlying stocks underperformed the market. ARK Invest CEO Cathie Wood has maintained her high level of conviction, despite ARKK's significant underperformance. Furthermore, ARKK ha...
Exact Sciences continues to record strong growth and is expected to report growth for the foreseeable future. Regardless of the steady revenue growth, the EXAS stock is under a lot of selling pressure as the overall market continues its downward trajectory. I believe the relentles...
Investors bailed out of tech and growth stocks even as tech insiders added more. Insider buying on the XLK ETF has surged to the highest in the last ten years. We discuss why the bottoming in tech and growth stocks could be forming. Subsequently, we believe the outperformance in growt...
The following slide deck was published by Exact Sciences Corporation in conjunction with their 2022 Q1 earnings call. For further details see: Exact Sciences Corporation 2022 Q1 - Results - Earnings Call Presentation
Updated ASCO Guidelines Strongly Recommend Use of the Oncotype DX Breast Recurrence Score® Test in Node-Negative and the Majority of Node-Positive Early-Stage Breast Cancer Patients PR Newswire Oncotype DX ® receives highest rating of all multigene te...
Image source: The Motley Fool. Exact Sciences (NASDAQ: EXAS) Q1 2022 Earnings Call Apr 26, 2022 , 5:00 p.m. ET Operator Continue reading For further details see: Exact Sciences (EXAS) Q1 2022 Earnings Call Transcript
Exact Sciences Corporation (EXAS) Q1 2022 Earnings Conference Call April 26, 2022, 05:00 PM ET Company Participants Megan Jones - Senior Director of IR Kevin Conroy - Chairman and CEO Jeff Elliott - CFO and COO Everett Cunningham - Chief Commercial Officer Conference Call Participants Brian W...
Exact Sciences (NASDAQ:EXAS), the maker of Cologuard cancer screening test raised its 2022 outlook after the company’s 1Q 2022 revenue exceeded Street forecasts on Tuesday. Total revenue for the quarter jumped ~21% YoY to $486.6M compared to $459.9M in the consensus. Total first quarte...
Exact Sciences press release (NASDAQ:EXAS): Q1 GAAP EPS of -$1.04 beats by $0.10. Revenue of $486.57M (+21.0% Y/Y) beats by $26.67M. COVID-19 testing revenue was $27.4 million during the first quarter. The company anticipates revenue of $1.99B - $2.03B during 2022 vs. consensus estimate...
News, Short Squeeze, Breakout and More Instantly...
Exact Sciences Corporation Company Name:
EXAS Stock Symbol:
NASDAQ Market:
Exact Sciences Corporation Website:
2024-07-11 08:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-08 08:30:00 ET To say that Exact Sciences (NASDAQ: EXAS) hasn't performed well on the stock market this year would be an understatement. Shares of the cancer-focused biotech are down by 41%. However, the healthcare company still has some fans on Wall Street. Cathie Wood ...
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its second quarter 2024 financial results after the close of the U.S. financial markets on July 31, 2024. Following the release, company management w...